ALVO
Alvotech Charts Course for Continued Growth in Biosimilar Market
In a recent conference call to discuss its Q4 2025 and full year 2025 earnings, Alvotech outlined its plans for continued growth in the biosimilar market. The company's leadership team presented on key highlights from the past year, including expanding commercial footprint, advancing pipeline programs, and strengthening financial